Emerging Therapeutic Strategies in Small-Cell Lung Cancer: From Adaptive Resistance to Precision Therapy
Pharmaceuticals · 2026-08-02 · 19 (8) · 1217
DOI: 10.3390/ph19081217 ↗At a glance
Übersichtsarbeit in Pharmaceuticals, published online on 2026-08-02. Written by Jun Kim and 1 co-authors. Institution: Department of Chemistry, Soongsil University, Seoul 06978, Republic of Korea. 81 references. The full text is freely available (open access, CC BY 4.0). Funded by: Ministry of Education.
Abstract (original language)
Background/Objectives: Small-cell lung cancer (SCLC) remains one of the most therapeutically challenging malignancies despite recent advances in chemoimmunotherapy. Although platinum–etoposide combined with programmed death ligand 1 (PD-L1) blockade has modestly improved survival in extensive-stage disease, most patients ultimately develop treatment resistance. This review examines the evolving biological basis of therapeutic resistance and discusses how emerging treatment strategies may be integrated into biologically informed clinical development.
Methods
We conducted a narrative review of recent translational studies, clinical trials, regulatory updates, and major oncology meeting presentations addressing emerging therapeutic strategies, biomarkers, and adaptive resistance mechanisms in SCLC.
Results
Advances in molecular profiling have established that SCLC comprises dynamically evolving transcriptional states characterized by lineage plasticity, replication-stress dependency, immune suppression, and antigen remodeling. These biological insights have accelerated the development of delta-like ligand 3 (DLL3)-directed immune-redirection strategies, next-generation antibody–drug conjugates, DNA damage response-targeting therapies, and epigenetic approaches. Across these platforms, however, clinical translation remains constrained by antigen heterogeneity, biomarker instability, lineage plasticity, immune dysfunction, and cumulative toxicity. We organize the available evidence across three clinically relevant treatment windows—induction, post-induction residual disease, and relapse—to clarify how therapeutic timing may influence the role and expected clinical performance of each strategy.
Conclusions
Future clinical development should prioritize the prospective validation of dynamic biomarkers and treatment strategies tailored to specific disease stages. Such an approach may improve patient selection, guide therapeutic sequencing, and increase the durability of treatment benefit in extensive-stage SCLC.
Subjects
Author keywords
Authors and institutions
- Department of Chemistry, Soongsil University, Seoul 06978, Republic of Korea.
- AI-Bio Convergence Research Institute, Soongsil University, Seoul 06978, Republic of Korea.
ORCID profiles: Jun Kim
Funding
- Ministry of Education
Cite
APA
Kim, J., & Kang, S. (2026). Emerging Therapeutic Strategies in Small-Cell Lung Cancer: From Adaptive Resistance to Precision Therapy. Pharmaceuticals, 19(8), 1217. https://doi.org/10.3390/ph19081217
Vancouver
Kim J, Kang S. Emerging Therapeutic Strategies in Small-Cell Lung Cancer: From Adaptive Resistance to Precision Therapy. Pharmaceuticals. 2026;19(8):1217. doi:10.3390/ph19081217
BibTeX
@article{Kim2026,
author = {Kim, Jun and Kang, Seounghun},
title = {Emerging Therapeutic Strategies in Small-Cell Lung Cancer: From Adaptive Resistance to Precision Therapy},
journal = {Pharmaceuticals},
year = {2026},
volume = {19},
number = {8},
pages = {1217},
doi = {10.3390/ph19081217}
}
EUVIMED